Cytokine storm in COVID-19 infection 新冠病毒感染引發的細胞激素風暴

臺北榮民總醫院內科部過敏免疫風濕科 主治醫師國立陽明大學醫學系、臺北醫學大學醫學系 部定副教授 廖顯宗

Since 2019-12, cases with a new type of viral pneumonia were noted in China. A new coronavirus-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was identified to be a pathogen and the disease was named as coronavirus infectious disease-2019 (COVID-19). With the number of confirmed cases and deaths rapidly spreading, the COVID-19 pandemic is a crucial and global issue. Accumulating evidence disclosed that patients with severe SARS-CoV-2 infection may present with cytokine storm, also called cytokine releasing syndrome. It was like the pathogenesis of SARS and MERS with higher plasma levels of proinflammatory cytokines in patients with severe COVID-19. Pathological findings from patients died of severe SARS-CoV-2 infection related cytokine storm revealed ARDS with bilateral diffuse alveolar damage with cellular fibromyxoid exudates. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. We will introduce the view of targeting the pathway in COVID-19 related cytokine storm.